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In the past few months, 2 main streams of research have dominated the panorama of myelodysplastic syndrome
(MDS) investigations: deepening the insight into the pathogenic role, hierarchy, and prognostic effect of somatic
mutations and, as a consequence, into the effect of inherited congenital predisposing conditions and the second,
quite interlinked with the first, analyzing inflammation and innate immunity in patients with MDS. The research devoted
to clarifying the mechanisms of action and mechanisms of resistance to hypomethylating agents has also advanced,
mostly resulting from different approaches to the study of DNA methylation. Recent observations have reinforced
support for targeted therapies for selected subgroups of MDS patients.
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The diagnosis of myelodysplastic syndromes (MDSs) has been
based on the morphologic assessment of dysplastic hematopoietic
progenitor cells of the various lineages, with the characteristic fea-
tures of dysplasia, which are subtly different from the dysplasia
secondary to inflammation or chronic disease, and a predetermined
minimum percentage (10%) of abnormal cells.1 However, this
diagnostic approach presents relevant difficulties and therefore re-
quires high expertise and is time consuming. The analysis of MDS
bone marrow aspirates is subjective, depending on the interpretation
of the morphologic features by the physician performing the anal-
ysis.2 These could be the reasons why some diagnoses of MDS are
dubious and require confirmation by abnormal cytogenetic and flow
cytometric analysis findings.2,3 The latter method has been
increasingly used in the idea of facilitating detection of marrow
dysplasia. However, high expertise is also required for the evalua-
tion, which has a number of limitations, diagnostically determi-
nant.3 Although in the scientific MDS community, all these issues
have been frequent subjects of discussion, it is clear that the pres-
ence of genetic abnormalities is fundamental to the diagnosis and
prognosis of MDS.4,5MDS Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Flor-
ence, Italy
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https://doi.org/10.1016/j.clml.2018.05.013The international prognostic scoring system (IPSS) and IPSS-
revised (IPSS-R)5,6 are routinely applied to stratify MDS, from a
prognostic viewpoint, into lower risk and higher risk. IPSS-R
prognostic scoring is strongly influenced by the classified cytoge-
netic abnormalities and, less than with the previous IPSS version,
the marrow blast percentage and depth of cytopenia. The risk is
defined by these variables and is related to overall survival and the
propensity to develop acute leukemia and, in fact, allow for good
stratification of MDS patients. In the IPSS-R, the presence of
dysplasia and the number of dysplastic lineages were not given
relevant weight, although both are determinant for the World
Health Organization (WHO) diagnosis of MDS. Nevertheless, the
IPSS-R is good but not sufficient to encompass the level of recog-
nized heterogeneity of MDS in terms of outcome and disease
behavior. The WHO-based prognostic scoring system-revised,
another prognostic scoring system, also relies on the morphologic
diagnosis of the type of dysplasia and seems to be more successful in
the prognostic stratification of MDS cases.7
In the past few years, the increasingly sophisticated methods of
molecular analysis have allowed for the characterization of the
frequent somatic mutations present in MDS. Somatic mutations are
present in nearly 90% of cases of MDS (Figure 1). Because of their
high frequency, knowledge of the specific mutations could improve
the prognostic evaluation of the 50% to 60% of MDS patients with
a normal karyotype.8 However, the effect of the 40 more frequent
somatic mutations on the natural history of MDS has not yet been
completely ascertained.9 The recent WHO classification has
included the spliceosome gene mutation SF3B1 as the onlyClinical Lymphoma, Myeloma & Leukemia August 2018 - 495
Figure 1 Recurrent Somatic Mutations and Their Relative
Frequency in Myelodysplastic Syndrome
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Abbreviations: BM ¼ bone marrow; BSC ¼ best supportive care; CCUS ¼ clonal cytopenias of
undetermined significance; GF ¼ hematopoietic growth factor (eg, epoetin); HMA ¼ hypo-
methylating agent (eg, azacitidine); HSCT ¼ hematopoietic stem cell transplantation;
IMiD ¼ immunomodulatory drug (eg, lenalidomide); IST ¼ immunosuppressive therapy;
Obs ¼ observation. Modified, with permission, from Steensma et al17 and Bejar et al.18
496 -
SOHO Updates and Open Questions for MDSdeterminant for the MDS subtype.1 The importance of single
mutations, co-mutations, and variant allele frequency of each mu-
tation is under study by several groups. The huge international
effort led by the International Working Group for the Prognosis of
MDS is evaluating the clinical significance of somatic mutations
using next generation sequencing (NGS) of material from w5000
cases of MDS with complete clinical annotations obtained from
several hematologic centers worldwide. The results will give relevant
information to the community and will most probably drive future
classification of these diseases. Although the final results of that
study are not yet available, the investigators have demonstrated the
relevance of the number and types of mutations in MDS in a
smaller cohort of cases.9-12
With these observations, it is intuitive that the diagnosis of MDS
is shifting from the use of morphology to molecular analysis. In the
past few months, even the role of cytogenetic evaluation has been
under discussion. Moreover, it is without doubt true that cytopenias
without dysplasia can be difficult, and the definite diagnosis of their
nature is often a challenge. The question remains regarding how to
diagnosis MDS and the definition of MDS, and which will be the
most reliable parameters and methods to apply. However, the
“molecular approach” to hematopoiesis, which seemed able to solve
the difficulties related to the diagnosis of MDS and its heterogeneity
has provided information on a very complex scenario and rendered
diagnostic applications in the context of MDS less straightforward.
Clonal Hematopoiesis and the
Difficult Diagnosis of MDS
The existence of clonal hemopoiesis, which does not always
correlate with neoplastic diseases, has long been known and assessed
using different methods.13 These include evaluating the phenotype
with flow cytometry and protein isoform determination, evaluating
the genotype with X gene inactivation, T-cell receptor rearrange-
ments and immunoglobulin rearrangements using cytogenetics/
array comparative genomic hybridization/single nucleotide poly-
morphism array, and, more recently, NGS.
Deep sequencing techniques have demonstrated the incidence
and frequency of clonal hematopoiesis. In 2014, 3 relevant
studies14-16 reported the presence of the somatic mutations most
frequently observed in MDS in very large non-MDS populations.
Mutations of DNMT3a, ASXL1, TET2, Jak2, TP53, and SF3B1
genes and others were reported to be age related and to correlateClinical Lymphoma, Myeloma & Leukemia August 2018with adverse outcome and the propensity to develop coronary heart
disease and hematologic neoplasms.14-16 Subsequent to these ob-
servations, some small acronyms were created to define the different
conditions and were added to the already used ICUS (idiopathic
cytopenia of unknown significance) and IDUS (idiopathic dysplasia
of unknown significance). These included CHIP/ARCH (clonal
hemopoiesis of indeterminate potential/age-related clonal hemo-
poiesis) and CCUS (clonal cytopenia of unknown significance;
Figure 2).17 For CHIP, clonality has been defined by the presence
of MDS-associated genes, including DNMT3A, ASXL1, TET2,
and JAK2, with loss of function. Individuals with CHIP have no
clinical disorder and little propensity to develop MDS (0.5%-1%
annually). However, CHIP is present in the same population that
usually develops MDS (ie, 15% of those aged > 70 years); thus, the
parallel term ARCH was created. It is not clear whether this event is
triggered by specific factors such as smoking, radiation, chemo-
therapy, or inflammation, is a stochastic event, or occurs with
hereditary or predisposing conditions.17 However, CHIP, which has
somehow been assimilated to MGUS (monoclonal gammopathy of
undetermined significance) and MBL (monoclonal B-cell lympho-
cytosis), is not so innocent. It can be a precursor to therapy-related
MDS and therapy-related acute myeloid leukemia (AML) in cancer
patients after chemotherapy.19 CHIP has been demonstrated in
62% of cases before therapy-related AML/MDS compared with
CHIP in 27% of controls. The variant allele frequency (VAF)
generally increases in the case of progression to MDS or AML
(Figure 2). Moreover, exposure to radiation therapy or tobacco use
increases the risk of CHIP/ARCH more than chemotherapy expo-
sure and has been found in w25% of solid tumor patients.20 Thus,
the presence of CHIP/ARCH should be carefully evaluated before
therapeutic decisions. In addition, it could be more common than
that reported in hotspot-focused studies.20
Valeria SantiniTherefore, it is necessary to determine the support that deep
sequencing techniques might provide to the diagnosis of MDS in
difficult cases. The presence of somatic mutations in patients with
cytopenia (ie, CCUS) is predictive of the evolution (14 times greater
probability) to MDS compared with that of unmutated ICUS.21
CCUS is a clonal condition, without evidence of relevant clinical
alterations; however, an increase in clonal burden leads to pro-
gression to defined overt MDS18 (Figure 2). In contrast, the
number of somatic mutations (> 2) and the size of the mutant
clone (VAF > 0.10) were shown to have significant predictive value
for the diagnosis of MDS.21 However, not all mutations have the
same value, and specific MDS mutations such as spliceosome gene
mutations will be more strongly suggestive of a myeloid neoplasm.21
Therefore, careful integration of the molecular data could support
the diagnosis in the negative or positive sense for those patients with
cytopenias without karyotype abnormalities and scarce marrow
dysplasia. However, prospective studies are needed. Although
routine NGS could be helpful in defining the presence and size of
the mutations in suspected MDS cases, a number of open questions
remain before implementing this approach into routine clinical
practice. In summary, in 2018, we can affirm that mutations cannot
be used as surrogate for the clinical diagnosis of MDS (with
exclusion of SF3B1 in the presence of 5% ring sideroblasts in
accordance with the WHO guidelines). If somatic mutations are
present, it is mandatory to evaluate the type and VAF, especially in
elderly patients. CCUS patients require very careful monitoring.
The presence of CHIP has clinical implications for patients with
solid tumors regarding the choice of therapy. However, the absence
of somatic mutations in patients with ICUS or IDUS might only
suggest and not definitively exclude an MDS diagnosis.
Somatic Mutations in MDS:
Prognostic Value and Therapeutic
Targeting
If the “molecular diagnosis” of MDS still presents problems, the
role of somatic mutations as prognostic indicators has become rather
consolidated.10-12 First, the number of somatic mutations carried by
a patient with MDS will correlate with leukemia-free survival (worst
with > 6 mutations).10 However, it has also been correlated with a
significantly inferior response to erythropoietic-stimulating agents in
lower risk MDS cases in which the clinical features predicted the
response22 to hypomethylating agents (HMAs)23 and lenalidomide
in non-del5q MDS.24 The occurrence of multiple mutations might,
therefore, be considered a hallmark of aggressive disease and resis-
tance to standard treatments.
The independent prognostic value of specific mutations was
ascertained years earlier for MDS presenting with TP53, EZH2,
ETV6, RUNX1, and ASXL1, which are predictors of poor overall
survival.25 In a particular subtype of MDS, with del5q, a great
proportion of patients will have no or only 1 somatic mutation.
Only 7 genes have shown mutation frequencies > 5%: SF3B1,
DNMT3A, TP53, TET2, CSNK1A1, ASXL1, JAK2. Also, their
relative pattern of frequency has been similar to that of all MDS
cases, with the exception of TP53, which has shown more frequent
mutations.26 TP53 mutations in MDS with del5q confer a poor
prognosis, with a decreased response to lenalidomide and a greater
propensity to progression to AML in a patient with MDS with anotherwise good outcome.27 The acquisition of TP53 and expansion
of the mutated clone seems to occur during lenalidomide treat-
ment.27 The evaluation of TP53 mutations and the size of the
mutated clone should thus be evaluated in all cases of MDS with
del5q found at baseline owing to the evident clinical implications.
In terms of prognostic importance, not all mutations are equal,
and their effect depends on the presence of co-mutations and the
phenotype of MDS in which they arise, allowing for a possible
molecular classification of MDS.28 TP53, U2AF1, RUNX1,
ASXL1, EZH2, and SF3B1 are significant for overall survival on
multivariate analysis for all MDS subtypes. In particular, the SF3B1
mutation is a major clustering criterion per se and identifies a
distinct subset of MDS with a favorable prognosis, irrespective of
the classification criteria used and the presence of ring side-
roblasts.28,29 Thus, it has been included in the most recent WHO
classification.1
The pathogenesis of MDS is becoming clearer owing to the
evaluation of genetic alterations (both mutations and copy number
alterations) that modify the molecular pathways and link genotype
to phenotype. The increasing knowledge of the events leading to
these diseases has rendered their modulation at least thinkable and
has already supported more focused therapeutic decisions.30 In
practice, evaluation of the mutational pattern of MDS in patients
undergoing hematopoietic stem cell transplantation (HSCT) might
in principle provide important independent prognostication in
addition to the clinical factors. Mutations of TP53 were reported by
3 different investigators as the most potent indicators of a dismal
outcome after HSCT.31-33 If TP53 is unmutated, the presence of
ASXL1 and RUNX131 or RAS pathway mutations in MDS/
myeloproliferative neoplasm and JAK2 mutations32 are predictors of
a poor outcome.
Although the pathogenetic and prognostic role played by specific
mutations and co-mutations has been investigated, another
important aspect of research is the importance of the hierarchical
clonal order of these somatic mutations in determining the MDS
phenotype. Founder mutations compared with subclonal mutations
and the dynamic characteristics of specific mutations (sweeping,
persistent, or vanishing) all contribute to generate the heterogeneity
of subtypes of MDS, their clonal evolution, and differing natural
histories.34 The top 5 dominant mutations are, as expected, SF3B1,
TET2, SRSF2, DNMT3A, and ASXL1. Somatic mutations in
MDS constitute possible therapeutic targets, and several mutation-
specific agents are under investigation in clinical studies.
Isocitrate dehydrogenase IDH1 and IDH2 genes are not very
frequently mutated in MDS (5%-12% of cases). However, 2 spe-
cific inhibitors, ivosidenib (AG-120) and enasidenib (AG-221), act
by reducing the abnormal production of 2-hydroxyglutarate and
promote MDS cellular differentiation. However, these do not
necessarily eliminate the IDH1 or IDH2 mutated clones or change
their VAFs. These agents are under clinical evaluation for MDS.
The preliminary results of a phase I clinical trial (ClinicalTrials.gov
identifier, NCT02074839) with ivosidenib in IDH1-mutated R7R
AML and MDS indicated a 21% complete remission and 41%
overall response rate.35 Enasidenib has been approved by the Food
and Drug Administration for IDH2-mutated relapsed AML and
was used for 30 AML/MDS patients in the registration trial with an
overall response rate of 40%. For the patients with refractory orClinical Lymphoma, Myeloma & Leukemia August 2018 - 497
Figure 3 Germline Predisposition to Myeloid Neoplasia
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MDS ¼ myelodysplastic syndrome. Modified from Niemeyer CM oral communication.
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498 -relapsed MDS after HMAs and carrying mutated IDH2, 50%
showed a treatment response.36
Spliceosome gene mutations are very frequent in MDS, and
targeting agents have been investigated. The pleiotropic function of
many of these genes has led to first failure in therapeutic attempts
with the E7107 compound owing to the important side effects.37
Clinical studies of the oral spliceosome inhibitor H3B-8800 for
MDS carrying mutations in various spliceosome genes are ongoing
after the preclinical demonstration of their activity because H3B-
8800 binds to the mutant and wild-type SF3b complex but exerts
its cytotoxic activity only on mutant cells, exploiting the “spliceo-
some insufficiency” of the mutated cells.38 Although not directed
specifically against SF3B1-mutated MDS, the 2 transforming
growth factor-b pathway inhibitors luspatercept and sotatercept
have demonstrated in phase II studies selective clinical activity in
this subtype of MDS.39,40 Therapy with these agents, especially
luspatercept, has led to a > 70% response rate in SF3B1-mutated
cases, with rather stable transfusion independence in those with
lower risk severely anemic MDS. It is possible that such agents are
acting only indirectly in cases in which transforming growth factor-
b pathways is highly stimulated instead of on the mutation itself.
Given the important role of mutant TP53, it constitutes a rele-
vant target for therapy. Although not yet studied in MDS, it has
become clear that TP53 targeting is possible, both directly and
indirectly, with a series of agents such as idasanutlin,41 an MDM2
inhibitor in evaluation to treat AML, and similar to APR246,42
which stabilizes the mutant TP53 in its wild-type conformation,
activating downstream pathways and restoring tumor suppressor
function. It has been evaluated in a phase I clinical study of he-
matologic malignancies.43
Reactivating apoptosis, the Bcl2 inhibitor venetoclax works
independently from the presence of TP53 mutations and has shown
clinical activity in AML and MDS/AML.44,45 AML patients with
epigenetic regulating and splicing gene mutations responded to
venetoclax plus low-dose cytarabine in 68% of cases.
Genetic Predisposition to MDS
The WHO 2016 classification1 introduced the category of
myeloid neoplasms with familial predisposition (Figure 3). Aware-
ness has been increasing of a possible inherited genetic defect in
younger patients with MDS. In addition, the detection of such
predisposing conditions has become easier and more frequent with
the availability of deep sequencing techniques.
Although an inherited predisposition to cancer has long been
known, the knowledge of a familial predisposition has been better
defined for solid tumors with a subsequent effect on therapy and
has been underestimated in MDS. Several genetic abnormalities
and germline mutations have been correlated with a predisposition
to MDS that could develop not only at young age but also in adult
and elderly patients. The demonstration of SAMD9 and SAMD9L
mutations in an adult with an alteration of chromosome 7 can lead
to the diagnosis of MDS with an inherited genetic predisposition.
Thus, recognition of such mutations and alterations is crucial for
the choice of transplantation donors outside the family. Similarly,
the cryptic variant of dyskeratosis congenita lacking the typical
clinical signs can be diagnosed only using molecular techniques,
provided that the evaluation of the mutations affecting the differentClinical Lymphoma, Myeloma & Leukemia August 2018telomere biology genes is included in the MDS routine diagnostic
panel.
Lindsley et al32 identified a group of MDS patients aged < 40
years with compound heterozygous mutations in the Shwachman-
Diamond syndrome-associated SBDS gene. These patients had a
poor prognosis, and all patients with biallelic SBDS mutations
presented with somatic TP53 mutations. None had a recognized
diagnosis of Shwachman-Diamond syndrome.32 Similarly, aware-
ness in the nonpediatric setting of the clinical manifestations of
congenital alterations that can mimic MDS (and, in fact, can pre-
dispose to MDS/AML, such as familial thrombocytopenia with
germline ANKRD26 mutation) can avoid mistreatment of wrongly
diagnosed MDS.46
Finally, a different situation is present in the case of inherited
disease such as congenital neutropenia, in which clonal hemato-
poiesis and progression to MDS and AML is not determined by
hematopoietic stresses such as therapy with granulocyte colony-
stimulating factors and the mutation burden is not increased.47
Patients with de novo MDS presenting at a younger age
(< 50 years), patients with MDS and a family history of AML, and
patients with MDS and peculiar extrahematologic symptoms should
prompt molecular assessment for inherited genetic conditions pre-
disposing to MDS.48 A series of actions should, therefore, be
introduced into the routine examination of these peculiar cases.
These include taking an accurate family and personal history to
search for signs and symptoms of congenital syndromes, performing
a mutational analysis for the genes involved in inherited predispo-
sition, and selection of an accurate HSCT donor to completely
avoid a related-matched donor generating slow engraftment and,
frequently, donor-derived leukemia. The most relevant implication
is the need for family genetic counseling, given the known antici-
pation of onset through the generations.
Inflammation and MDS
MDS research has recently focused on inflammation. The pres-
ence of inflammation increases with age (“inflammaging”) and
Valeria Santinicould be the trigger to clonal hematopoiesis. A chronic mild
multifactorial inflammatory condition could induce an innate im-
mune response and evolve into an oligoclonal T-cell response,
resulting in subversion of the immune response and progression
from clonal hematopoiesis to low-risk MDS and then high-risk
MDS (Kordasti, personal communication, 2018).
In contrast, the presence of CHIP has been shown to correlate
with the development of coronary heart disease.49 Patients with
CHIP had a 4 times greater risk of myocardial infarction, and 2
TET2 knockout mouse models had an increased atherogenesis and
markers of activated inflammation.49 Finally, blocking inflamma-
some impairs the development of atherosclerosis.
Methylation Abnormalities and
Response to HMAs
The HMAs azacitidine and decitabine are the standard treat-
ment of MDS. Patients respond to these therapies in 40% to 60%
of cases, transiently, and the dysplastic clone will be maintained
despite hematologic improvement. The resistance to HMA treat-
ment is, at present, one of the major problems in the management
of MDS. Prediction of the response and distinction of the causes
of primary versus secondary resistance are of paramount
importance.
The aberrant methylation typical of MDS is determined by the
presence of recurrent mutations in epigenetic regulatory genes, with
a frequent DNA hypermethylation phenotype and decreased
5-hydroxymethylcytosine formation. Restoration of function of 1 of
these genes, such as TET2, will eliminate progression of the
disease.50
The differences in the mode of action and activity between
azacitidine and decitabine rely on different DNA uptake, with the
azacitidine intracellular dynamic determinant for activity, but
probably also on other factors.51 The mechanisms of resistance to
HMAs are multifactorial.52 The recently demonstrated markers of
sensitivity such as TET2 mutations,53 TP53 mutations,54 over-
expression of nucleotide metabolizing enzymes, such as UCK1,55
and cytokines CXCL4 and CXCL756 must be consolidated.
Novel schedules, doses,57 and combinations with numerous other
agents have been investigated to increase the efficacy of these drugs
and have been previously reported.58-60
New HMAs are under evaluation in the hopes of obtaining
increased clinical efficacy. These include guadecitabine, previously
known as SGI-110, a dinucleotide of decitabine and deoxy-
guanosine, that prolongs the in vivo exposure of decitabine by
protecting it from deamination.61 An oral formulation of decita-
bine, ASTX727 (decitabine 35 mg/cedazuridine 100 mg) is under
evaluation in ongoing clinical trials of MDS.62
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